Author: Langellotto, Fernanda; Seiler, Benjamin T.; Yu, Jingyou; Cartwright, Mark J.; White, Des; Yeager, Chyenne; Super, Michael; Doherty, Edward J.; Barouch, Dan H.; Mooney, David J.
Title: A rapidly adaptable biomaterial vaccine for SARS-CoV-2 Cord-id: m7h2rv0f Document date: 2020_7_7
ID: m7h2rv0f
Snippet: The global COVID-19 pandemic motivates accelerated research to develop safe and efficacious vaccines. To address this need, we leveraged a biomaterial vaccine technology that consists of mesoporous silica rods (MSRs) that provide a sustained release of granulocyte-macrophage colony-stimulating factor (GM-CSF) and adjuvants to concentrate and mature antigen-presenting cells at the vaccine site. Here we explored the humoral responses resulting from the use of monophosphoryl lipid A (MPLA) as the a
Document: The global COVID-19 pandemic motivates accelerated research to develop safe and efficacious vaccines. To address this need, we leveraged a biomaterial vaccine technology that consists of mesoporous silica rods (MSRs) that provide a sustained release of granulocyte-macrophage colony-stimulating factor (GM-CSF) and adjuvants to concentrate and mature antigen-presenting cells at the vaccine site. Here we explored the humoral responses resulting from the use of monophosphoryl lipid A (MPLA) as the adjuvant and SARS-CoV-2 spike proteins S1, S2, the nucleocapsid (N) protein, and receptor binding domain (RBD) as the target antigens. The dose of antigen and impact of pre-manufacturing of vaccines as versus loading antigen just-in-time was explored in these studies. Single shot MSR vaccines induced rapid and robust antibody titers to the presented antigens, even without the use of a boost, and sera from vaccinated animals demonstrated neutralizing activity against a SARS-CoV-2 pseudovirus. Overall, these results suggest the MSR vaccine system may provide potent protective immunity when utilized to present SARS-CoV-2 antigens.
Search related documents:
Co phrase search for related documents- acute respiratory and adjuvant antigen: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory and adjuvant immune response: 1, 2, 3, 4
- acute respiratory and adjuvant release: 1
- acute respiratory and local release: 1, 2, 3, 4
- acute respiratory and low response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42
- acute respiratory and luciferase reporter: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30
- acute respiratory and luciferase reporter gene: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41
- acute respiratory and lyophilized vaccine: 1, 2
- adjuvant antigen and low response: 1, 2
- adjuvant antigen and lymph node: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date